{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:12:17Z","timestamp":1772748737148,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":225,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p>A multicentre phase II trial was conducted to evaluate the efficacy and toxicity of gemcitabine in patients with refractory or relapsed indolent non\u2010Hodgkin's lymphoma. Thirty\u2010six patients were enrolled onto the study, including 11 cases of mantle cell lymphoma (MCL), 10 cases of chronic lymphocytic leukaemia (CLL)\/lymphocytic lymphoma, nine cases of follicular lymphoma, four cases of lymphoplasmacytic lymphoma and two cases of T\u2010cell lymphoma. Gemcitabine 1\u2003g\/m<jats:sup>2<\/jats:sup> was administered as a 30\u2010min infusion on d\u20031, 8 and 15 of a 28\u2010d schedule, up to a maximum of six cycles. Complete responses were observed in two patients with MCL, and partial responses were observed in seven patients, including three patients with CLL\/lymphocytic lymphoma, two patients with T\u2010cell lymphoma, one patient with MCL and one patient with follicular lymphoma. Minor responses were observed in three patients, including two patients with MCL and one patient with CLL. The median duration of response was 150\u2003d and the overall progression\u2010free survival was 342\u2003d. Haematological toxicity was observed as grade 3\u20134 leucopenia in 12 patients (33%) and grade 3\u20134 thrombocytopenia in 18 patients (50%). Severe non\u2010haematological toxicity included one case of fatal veno\u2010occlusive disease, one case of thrombotic microangiopathy leading to terminal renal failure, one case of capillary leak syndrome, one case of myocardial infarction and drug\u2010induced fever in two patients. These data suggest that gemcitabine displays activity in patients with MCL and CLL\/lymphocytic lymphoma. Haematological toxicity was frequent in these heavily treated patients. Severe non\u2010haematological toxicity was significant and should be taken into account in the design of future trials.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02795.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:34:18Z","timestamp":1047364458000},"page":"772-778","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Gemcitabine as a single agent in the treatment of relapsed or refractory low\u2010grade non\u2010Hodgkin's lymphoma"],"prefix":"10.1111","volume":"113","author":[{"given":"C.","family":"Dumontet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Solal\u2010Celigny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bouafia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Hequet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"S8","article-title":"Weekly gemcitabine and monthly cisplatin for advanced non\u2010small cell lung carcinoma","volume":"24","author":"Abratt R.P.","year":"1997","journal-title":"Seminars in Oncology"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00667.x"},{"key":"e_1_2_5_4_1","first-page":"5","article-title":"Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL","volume":"35","author":"Binet J.L.","year":"1993","journal-title":"Nouvelle Revue of French Haematology"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830290307"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199303183281116"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008225930573"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3786"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.20.1779"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2"},{"key":"e_1_2_5_12_1","first-page":"32","article-title":"Gemcitabine safety overview","volume":"23","author":"Green M.R.","year":"1996","journal-title":"Seminars in Oncology"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.140351"},{"key":"e_1_2_5_14_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/annonc\/11.suppl_1.S3","article-title":"Lymphoma classification \u2013 from controversy to consensus: the R.E.A.L. & WHO Classification of lymphoid neoplasms","volume":"11","author":"Harris N.L.","year":"2000","journal-title":"Annals of Oncology"},{"key":"e_1_2_5_15_1","first-page":"11","article-title":"Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism","volume":"22","author":"Heinemann V.","year":"1995","journal-title":"Seminars in Oncology"},{"key":"e_1_2_5_16_1","first-page":"28","article-title":"Fludarabine single\u2010agent therapy for relapsed low\u2010grade non\u2010Hodgkin's lymphomas: a phase II study of the German Low\u2010Grade Non\u2010Hodgkin's Lymphoma Study Group","volume":"20","author":"Hiddemann W.","year":"1993","journal-title":"Seminars in Oncology"},{"key":"e_1_2_5_17_1","first-page":"63","article-title":"Fludarabine phosphate therapy of non\u2010Hodgkin's lymphoma","volume":"17","author":"Hochster H.","year":"1990","journal-title":"Seminars in Oncology"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.28"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.921"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331979905001208"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000013525"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-7646(98)80047-2"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.588"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q"},{"key":"e_1_2_5_25_1","first-page":"24","article-title":"Fludarabine in low\u2010grade lymphoma","volume":"20","author":"Pigaditou A.","year":"1993","journal-title":"Seminars in Oncology"},{"key":"e_1_2_5_26_1","first-page":"19","article-title":"Docetaxel (Taxotere) and gemcitabine in combination therapy","volume":"26","author":"Rizvi N.A.","year":"1999","journal-title":"Seminars in Oncology"},{"key":"e_1_2_5_27_1","first-page":"943","article-title":"Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia","volume":"9","author":"Robertson L.E.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2615"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008307528519"},{"key":"e_1_2_5_30_1","first-page":"2766","article-title":"ESHAP chemotherapy for relapsed\/refractory non\u2010Hodgkin's lymphoma","volume":"12","author":"Sweetenham J.W.","year":"1994","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199512006-00005"},{"key":"e_1_2_5_32_1","first-page":"794","article-title":"In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells","volume":"84","author":"Tosi P.","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.117.117"},{"key":"e_1_2_5_34_1","first-page":"3106","volume-title":"Blood","author":"Waselenko J.K.","year":"1997"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2603"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1995.tb00269.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02795.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02795.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02795.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:13:24Z","timestamp":1695827604000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02795.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02795.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02795.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]},"assertion":[{"value":"2002-01-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}